

Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/26**

Canakinumab (Ilaris®)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Periodic Fever Syndromes:

Cryopyrin-Associated Periodic Syndromes (CAPS)

Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)

Ilaris is indicated for the treatment of TRAPS in adult and pediatric patients.

Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)

Ilaris is indicated for the treatment of HIDS and MKD in adult and pediatric patients.

Familial Mediterranean Fever (FMF)

Ilaris is indicated for the treatment of FMF in adult and pediatric patients.

Still's Disease (Adult-Onset Still's Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [sJIA])

Ilaris is indicated for the treatment of active Still's disease, including AOSD and sJIA in patients 2 years of age and older.

Gout Flares

Ilaris is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Compendial Uses

Pseudogout

All other indications are considered experimental/investigational and not medically necessary.

DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

This document has been classified as public information



Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/26**

Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) and Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)

Initial requests

Chart notes, medical record documentation, or laboratory result (if applicable) indicating number of active flares within the last 6 months and Physician's Global Assessment (PGA) score or C-reactive protein (CRP) level.

Familial Mediterranean Fever (FMF)

Initial requests

- Chart notes or medical record documentation indicating number of active flares within the last 6 months.
- Laboratory results, chart notes, or medical record documentation of CRP level.
- Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still's disease (AOSD)

Initial requests

Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable).

Continuation requests

Chart notes or medical record documentation supporting positive clinical response.

Gout and pseudogout flares

Initial requests

Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with one of the following:

- Cryopyrin-associated periodic syndromes (CAPS), TRAPS, HIDS/MKD, and FMF: rheumatologist or immunologist
- Systemic juvenile idiopathic arthritis (sJIA), AOSD, gout, and pseudogout: rheumatologist

COVERAGE CRITERIA

Periodic Fever Syndromes

Authorization of 12 months may be granted for members 4 years of age or older for treatment of CAPS when both of the following criteria are met:

- Member has a diagnosis of familial cold autoinflammatory syndrome (FCAS) with classic signs and symptoms (i.e., recurrent, intermittent fever and rash that were often exacerbated by exposure to generalized cool ambient temperature) or Muckle-Wells syndrome (MWS) with classic signs and symptoms (i.e., chronic fever and rash of waxing and waning intensity, sometimes exacerbated by exposure to generalized cool ambient temperature).
- Member has functional impairment limiting the activities of daily living.

Authorization of 12 months may be granted for treatment of TRAPS when both of the following criteria are met:

- Member has chronic or recurrent disease activity with active flares within the last 6 months.
- Physician's Global Assessment (PGA) score greater than or equal to 2 or C-reactive protein (CRP) greater than 10 mg/L.



Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/26**

Authorization of 12 months may be granted for treatment of HIDS/MKD when both of the following criteria are met:

- Member has had active flares within the last 6 months.
- Physician's Global Assessment (PGA) score greater than or equal to 2 or C-reactive protein (CRP) greater than 10 mg/L.

Authorization of 12 months may be granted for treatment of FMF when all of the following criteria are met:

- Member has active disease with flares within the last 6 months.
- C-reactive protein (CRP) greater than 10 mg/L.
- Member has had an inadequate response, intolerance, or contraindication to colchicine.

Still's Disease (Adult-Onset Still's Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [sJIA])

Authorization of 12 months may be granted for members 2 years of age or older who have previously received a biologic indicated for active sJIA or active AOSD.

Authorization of 12 months may be granted for members 2 years of age or older for treatment of active sJIA or active AOSD when the member has active systemic features (e.g., fever, evanescent rash, lymphadenopathy, hepatomegaly, splenomegaly, serositis).

Gout and Pseudogout Flares

Authorization of 12 months may be granted for adult members for the treatment of flares for gout and pseudogout (also known as calcium pyrophosphate deposition disease) when both of the following criteria are met:

- Member has experienced at least three flares in the last 12 months.
- Member has had an inadequate response, intolerance or contraindication to non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids.

CONTINUATION OF THERAPY

Still's Disease (Adult-Onset Still's Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [sJIA])

Authorization of 12 months may be granted for all members 2 years of age or older (including new members) who are using the requested medication for sJIA or AOSD and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

- Number of joints with active arthritis (e.g., swelling, pain, limitation of motion)
- Number of joints with limitation of movement
- Functional ability
- Systemic features (e.g., fever, evanescent rash, lymphadenopathy, hepatomegaly, splenomegaly, serositis)

Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

Authorization of 12 months may be granted for all members 4 years of age or older (including new members) who are using the requested medication for CAPS, including FCAS and MWS, and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.

All Other Indications



Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/26**

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for an indication outlined in the coverage criteria and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.

OTHER

For all indications: Member has been evaluated for tuberculosis (TB) infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.

For all indications: Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug.

MEDICATION QUANTITY LIMITS

Drug Name	Diagnosis	Maximum Dosing Regimen
Ilaris (Canakinumab)	Cryopyrin-Associated Periodic Syndromes (CAPS)	Route of Administration: Subcutaneous ≥4 year(s) ≥41kg 150mg every 8 weeks ≥4 year(s) 15 - <41kg 2mg/kg every 8 weeks. May increase to 3mg/kg for pediatric patients with an inadequate response
Ilaris (Canakinumab)	Gout Flares	Route of Administration: Subcutaneous ≥18 year(s) 150mg as a single dose. May repeat after at least 12 weeks for patients requiring re-treatment
Ilaris (Canakinumab)	Pseudogout	Route of Administration: Subcutaneous ≥18 year(s) 150mg as a single dose. May repeat after at least 12 weeks for patients requiring re-treatment
Ilaris (Canakinumab)	Still's Disease (Adult-Onset Still's Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA])	Route of Administration: Subcutaneous ≥2 year(s) 7.5 - <75kg 4mg/kg every 4 weeks ≥2 year(s) ≥75kg 300mg every 4 weeks
Ilaris (Canakinumab)	Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS) /Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF)	Route of Administration: Subcutaneous ≥41kg 150mg every 4 weeks. May increase to 300mg for patients with an inadequate response <41kg 2mg/kg every 4 weeks. May increase to 4mg/kg for patients with an inadequate response

Medical Policy Manual **Approved Rev: Do Not Implement until 10/31/26**

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Ilaris [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2024.
2. De Benedetti F, Gattorno M, Anton J, et al; Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. *N Engl J Med*. 2018;378:1908-19.
3. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med*. 2009;360(23):2416-2425.
4. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res*. 2013;65(10):1551-63.
5. DRUGDEX® System (electronic version). Truven Health Analytics, Ann Arbor, MI. Available at <http://www.micromedexsolutions.com> [available with subscription]. Accessed November 17, 2025.
6. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis*. 2017;76:29-42.
7. Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. *Ann Rheum Dis*. 2011;70:571-575.
8. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout [published correction appears in *Arthritis Care Res (Hoboken)*. 2020 Aug;72(8):1187]. *Arthritis Care Res (Hoboken)*. 2020;72(6):744-760.
9. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol*. 2022;74(4):553-569.
10. Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. *Semin Arthritis Rheum*. 2021;51(4):858-874.

EFFECTIVE DATE

10/31/2026

ID_CHS_2026